Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Serum β-amyloid 1–42 Levels as Alternative Non-invasive Screening Biomarker for Alzheimer’s Disease and Vascular Dementia in Indonesian Elderly Population

The Indonesian Biomedical Journal · Vol. 17 No. 6 (2025) · hlm. 600–606

DOI
10.18585/inabj.v17i6.3869
ISSN
2085-3297, 2355-9179
Terbit
2025-12-27
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Alzheimer’s disease (AD) and vascular dementia (VaD) impose a substantial public health burden in Indonesia; however, accessible blood-based biomarkers for early screening remain limited. Although cerebrospinal fluid β-amyloid 1–42 is an established biomarker, its invasive nature restricts its use for population-level screening. Therefore, it is necessary to have locally-produced serum β-amyloid 1–42 ELISA kit that is specifically designed for Indonesian elderly population. In this study, a locally-produced β-amyloid 1–42 ELISA kit was validated and used for the screening of AD, VaD and mild cognitive impairment (MCI) Indonesian population.METHODS: A cross-sectional study including 166 subjects: 31 AD, 34 VaD, 34 MCI patients, and 67 cognitively normal controls was conducted. All participants underwent cognitive assessments including Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment-Indonesian version (MoCA-Ina), as well as brain magnetic resonance imaging (MRI) 3-Tesla for the assessment of medial temporal atrophy/white matter changes. Fasting venous blood sampling was taken from each subjects for the measurement of serum β-amyloid 1-42 measurement using locally-produced ELISA kit.RESULTS: Median serum β-amyloid 1–42 levels were 11.03, 10.99, and 10.99 pg/mL for the AD, VaD, and MCI subjects, respectively. The β-amyloid 1–42 levels were correlated with MMSE scores in all group (AD: r=−0.455, p=0.010; VaD: r=−0.419, p=0.014; MCI: r=−0.412, p=0.015). The validity analysis of the locally-produced serum β-amyloid 1–42 ELISA kit, showed sensitivity of 94.12% (95% CI: 87.3–97.9), specificity of 80.36% (95% CI: 72.4–86.8), and diagnostic accuracy of 83.56% (95% CI: 77.2–88.5).CONCLUSION: Serum β-amyloid 1–42 levels are lower in AD and VaD subjects compared to MCI and control subjects. Serum β-amyloid 1-42 is inversely correlated with cognitive function across all groups based on MMSE score. Additionally, the locally-produced β-amyloid 1-42 ELISA kit demonstrated sensitivity of 94.12% and specificity of 80.36%, meeting Global CEO Initiative Consensus for pre-screening tools, supporting its potential as a scalable, non-invasive screening biomarker in Indonesian primary care settings.KEYWORDS: G-banding karyotyping, next generation sequencing, non-invasive prenatal testing

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 112 tautan kepenulisan bersama · 71 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Trisakti
  • Universitas Airlangga
  • University of Brawijaya
  • University of Indonesia
  • Padjadjaran University
  • Hasanuddin University
  • PT Prodia StemCell Indonesia (Indonesia)
  • Organisasi lain
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Andi WijayaHasanuddin University47
Anna MeilianaPadjadjaran University45
Muhammad Ihsan RizalUniversitas Trisakti6
Dewi RanggainiUniversitas Trisakti6
Melanie Sadono DjamilUniversitas Trisakti6
Janti SudionoUniversitas Trisakti4
Johni HalimUniversitas Trisakti4
Angliana ChouwPT Prodia StemCell Indonesia (Indonesia)4
Djanggan SargowoUniversity of Brawijaya4
Visi Endah PratitisAfiliasi tidak diketahui4
Maria CelinnaAfiliasi tidak diketahui4
Toshio KukitaKyushu University4
Wahyu WidowatiMaranatha Christian University3
Yanni DirgantaraPT Prodia StemCell Indonesia (Indonesia)3
Alifah Evi ScaniaUniversity of Indonesia3
Kyung Hoon LeeAfiliasi tidak diketahui3
Roya Khosravi‐FarBeth Israel Deaconess Medical Center3
Irawan YusufHasanuddin University3
Solachuddin Jauhari Arief IchwanUniversiti Brunei Darussalam3
Ketherin KetherinUniversitas Trisakti2
Tjandrawati MozefIndonesian Institute of Sciences2
Ardian RizalUniversity of Brawijaya2
Irma Ruslina DefiPadjadjaran University2
Tadahiko IijimaKyushu University2
Sonar Soni PanigoroRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo2
Herqutanto HerqutantoUniversity of Indonesia2
Andon HestiantoroRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo2
Nyoman Suci WidyastitiDiponegoro University2
Pudji RahajuUniversity of Brawijaya2
Ahmad Dian WahyudionoUniversity of Brawijaya2
Reza Gunadi RanuhUniversitas Airlangga2

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Serum β-amyloid 1–42 Levels as Alternative Non-invasive Screening Biomarker for Alzheimer’s Disease and Vascular Dementia in Indonesian Elderly Population</dc:title><dc:creator>Indah Aprianti Putri</dc:creator><dc:creator>Huda Shalahuddin Darusman</dc:creator><dc:creator>Muhammad Hamdan</dc:creator><dc:creator>Pukovisa Prawiroharjo</dc:creator><dc:creator>Budi Utomo</dc:creator><dc:creator>Jusak A. Nugraha</dc:creator><dc:creator>Yohanna Kusuma</dc:creator><dc:creator>Nurrani Mustika Dewi</dc:creator><dc:creator>Ferry Sandra</dc:creator><dc:subject>vascular dementia</dc:subject><dc:subject>non-invasive biomarkers</dc:subject><dc:subject>dementia screening</dc:subject><dc:subject>mild cognitive impairment</dc:subject><dc:subject>ELISA kit validation</dc:subject><dc:subject>diagnostic accuracy</dc:subject><dc:subject>cognitive impairment</dc:subject><dc:subject>blood-based biomarkers</dc:subject><dc:subject>medial temporal lobe atrophy</dc:subject><dc:subject>white matter changes</dc:subject><dc:description xml:lang="en">BACKGROUND: Alzheimer’s disease (AD) and vascular dementia (VaD) impose a substantial public health burden in Indonesia; however, accessible blood-based biomarkers for early screening remain limited. Although cerebrospinal fluid β-amyloid 1–42 is an established biomarker, its invasive nature restricts its use for population-level screening. Therefore, it is necessary to have locally-produced serum β-amyloid 1–42 ELISA kit that is specifically designed for Indonesian elderly population. In this study, a locally-produced β-amyloid 1–42 ELISA kit was validated and used for the screening of AD, VaD and mild cognitive impairment (MCI) Indonesian population.METHODS: A cross-sectional study including 166 subjects: 31 AD, 34 VaD, 34 MCI patients, and 67 cognitively normal controls was conducted. All participants underwent cognitive assessments including Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment-Indonesian version (MoCA-Ina), as well as brain magnetic resonance imaging (MRI) 3-Tesla for the assessment of medial temporal atrophy/white matter changes. Fasting venous blood sampling was taken from each subjects for the measurement of serum β-amyloid 1-42 measurement using locally-produced ELISA kit.RESULTS: Median serum β-amyloid 1–42 levels were 11.03, 10.99, and 10.99 pg/mL for the AD, VaD, and MCI subjects, respectively. The β-amyloid 1–42 levels were correlated with MMSE scores in all group (AD: r=−0.455, p=0.010; VaD: r=−0.419, p=0.014; MCI: r=−0.412, p=0.015). The validity analysis of the locally-produced serum β-amyloid 1–42 ELISA kit, showed sensitivity of 94.12% (95% CI: 87.3–97.9), specificity of 80.36% (95% CI: 72.4–86.8), and diagnostic accuracy of 83.56% (95% CI: 77.2–88.5).CONCLUSION: Serum β-amyloid 1–42 levels are lower in AD and VaD subjects compared to MCI and control subjects. Serum β-amyloid 1-42 is inversely correlated with cognitive function across all groups based on MMSE score. Additionally, the locally-produced β-amyloid 1-42 ELISA kit demonstrated sensitivity of 94.12% and specificity of 80.36%, meeting Global CEO Initiative Consensus for pre-screening tools, supporting its potential as a scalable, non-invasive screening biomarker in Indonesian primary care settings.KEYWORDS: G-banding karyotyping, next generation sequencing, non-invasive prenatal testing</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2025-12-27</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v17i6.3869</dc:identifier><dc:identifier>10.18585/inabj.v17i6.3869</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 17 No 6 (2025); 600-606</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/3869/816</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>